AUSTIN, Texas, July 19, 2021 /PRNewswire/ — Natera, Inc.. (Nasdaq: NTRA) (“Natera” or the “Firm”), a pioneer and world chief in cell-free DNA testing, at present reported preliminary outcomes for the quarter ended June 30, 2021 for quantity and income development.
The Firm’s income development charge within the second quarter of 2021 was the most important yr on yr development in its historical past as a publicly traded firm. Whole revenues for the second quarter of 2021 are anticipated to be roughly $138 million to $141 million, in contrast with whole revenues of $86.5 million for the second quarter of 2020, which represents roughly 60% yr on yr development. The Firm expects its product revenues for the second quarter of 2021 to be roughly $135 million to $137 million, in contrast with product revenues of $80.4 million for the second quarter of 2020, which represents roughly 70% yr on yr development.
The Firm’s quantity development charge within the second quarter of 2021 was additionally the most important yr on yr development in its historical past as a publicly traded firm. Through the second quarter of 2021, the Firm processed roughly 370,000 checks, in comparison with roughly 234,000 checks processed throughout the second quarter of 2020, which represents roughly 58% yr on yr development.
The Firm additionally expects that, throughout the second quarter of 2021, its Ladies’s Well being enterprise will probably be its first enterprise unit to realize money circulate breakeven1 operations, which represents a significant milestone for the Firm.
The Firm expects to acknowledge a loss from operations of roughly $113 million to $117 million for the second quarter of 2021, in comparison with a loss from operations of $51.7 million for the second quarter of 2020, reflecting the Firm’s elevated analysis and improvement and promoting, common and administrative prices in help of the commercialization of its new product choices, which are anticipated to proceed in subsequent quarters.
Natera is a pioneer and world chief in cell-free DNA testing from a easy blood draw. The mission of the Firm is to alter the administration of illness worldwide with a concentrate on ladies’s well being, oncology, and organ well being. Natera operates ISO 13485-certified and CAP-accredited laboratories licensed underneath the Scientific Laboratory Enchancment Amendments (CLIA) in San Carlos, California and Austin, Texas. It gives proprietary genetic testing providers to tell obstetricians, transplant physicians, oncologists, and most cancers researchers, together with biopharmaceutical firms, and genetic laboratories via its cloud-based software program platform.
This press launch accommodates forward-looking statements underneath the which means of the Non-public Securities Litigation Reform Act of 1995. All statements apart from statements of historic information contained on this press launch, together with the Firm’s preliminary monetary and working outcomes for the second quarter of fiscal 2021, are forward-looking statements. These forward-looking statements are topic to identified and unknown dangers and uncertainties which will trigger the Firm’s precise outcomes to vary materially, together with: the Firm’s preliminary monetary and working outcomes for the second quarter of fiscal 2021 are topic to materials modifications and changes because the Firm completes its monetary closing procedures and its monetary statements are reviewed by its exterior auditors; the Firm could also be unable to keep up its enterprise and operations as deliberate in mild of the COVID-19 pandemic; the Firm could also be unable to additional improve the use and adoption of Panorama and Horizon, via its direct gross sales efforts or via its laboratory companions, or to develop and efficiently commercialize new merchandise, together with Signatera and Prospera; the Firm has incurred losses since its inception and it anticipates that it’s going to proceed to incur losses for the foreseeable future; the Firm’s quarterly outcomes might fluctuate from interval to interval; the Firm’s estimates of market alternative and forecasts of market development might show to be inaccurate; the Firm could also be unable to compete efficiently with current or future services or products provided by its opponents; the Firm might have interaction in acquisitions, inclinations or different strategic transactions that won’t obtain our anticipated advantages and will in any other case disrupt the Firm’s enterprise, trigger dilution to its stockholders or scale back its monetary sources; the Firm is probably not profitable in commercializing its cloud-based distribution mannequin; the Firm’s merchandise might not carry out as anticipated; the outcomes of the Firm’s medical research, together with its SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Research, is probably not compelling to skilled societies or payors as supporting using its checks, notably within the average-risk being pregnant inhabitants or for microdeletions screening, or might not be capable to be replicated in later research required for regulatory approvals or clearances; if both of the Firm’s CLIA-certified laboratory services turns into inoperable, the Firm will probably be unable to carry out its checks and its enterprise will probably be harmed; the Firm depends on a restricted variety of suppliers or, in some instances, single suppliers, for a few of its laboratory devices and supplies and will not be capable to discover replacements or instantly transition to different suppliers; whether it is unable to efficiently scale its operations, the Firm’s enterprise might endure; the advertising and marketing, sale, and use of Panorama and the Firm’s different merchandise might end in substantial damages arising from product legal responsibility or skilled legal responsibility claims that exceed its sources; the Firm could also be unable to broaden third-party payer protection and reimbursement for Panorama, Horizon and its different checks, and the Firm could also be required to refund reimbursements already obtained; third-party payers might withdraw protection or present decrease ranges of reimbursement resulting from altering insurance policies, billing complexities or different components, such because the elevated focus by third-party payers on requiring that prior authorization be obtained previous to conducting a check; if the FDA had been to start actively regulating its checks, the Firm might incur substantial prices and delays related to making an attempt to acquire premarket clearance or approval and incur prices related to complying with post-market controls; litigation or different proceedings, ensuing from both third social gathering claims of mental property infringement or third social gathering infringement of the Firm’s know-how, is dear, time-consuming and will restrict its capacity to commercialize its services or products; any incapability to successfully shield its proprietary know-how might hurt the Firm’s aggressive place or its model; and the Firm can not assure that will probably be in a position to service and adjust to its excellent debt obligations or obtain its expectations concerning the conversion of its excellent convertible notes. Extra dangers and uncertainties that would have an effect on the Firm’s monetary outcomes are included underneath the captions, “Threat Components” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” in its most up-to-date filings on Varieties 10-Okay and 10-Q and in different filings that the Firm makes with the SEC on occasion. These paperwork can be found on the Firm’s web site at www.natera.com underneath the Investor Relations part and on the SEC’s web site at www.sec.gov. Besides as required by legislation, the Firm assumes no obligation to replace any such forward-looking statements after the date of this launch.
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Kate Stabrawa, Communications, Natera, Inc., 720-318-4080 firstname.lastname@example.org
1 The Firm decided estimated constructive money circulate for the Ladies’s Well being enterprise by contemplating the preliminary revenues derived from its Ladies’s Well being merchandise within the second quarter of 2021, much less estimated price of revenues for the Ladies’s Well being merchandise and estimated working bills allotted to the Ladies’s Well being enterprise within the second quarter of 2021. These estimates exclude non-cash bills, equivalent to stock-based compensation.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/natera-reports-preliminary-second-quarter-2021-results-301336378.html
SOURCE Natera, Inc.